Extracellular Matrix Protection Factor 1 (ECPF-1), a novel inhibitor of Matrix Metalloprotease 13 (MMP-13) is chondroprotective in a serum-free culture model of primary human articular chondrocytes
Location
Philadelphia
Start Date
11-5-2016 1:00 PM
Description
The pathogenic process that defines osteoarthritis (OA) is the imbalance between excess degradation of the extracellular matrix in articular cartilage and a decreased ability of chondrocytes to remodel the matrix. There are many factors that contribute to this disease including unchecked actions of matrix metalloproteinase 13 (MMP-13), an enzyme specific for the breakdown of collagen type II which is the main component of cartilage extracellular matrix. We have developed a three-dimensional, serum-free culture system to rear primary, human articular chondrocytes. In this study, we tested the effects of a member of the novel class of MMP inhibitors, Extracellular Matrix Protection Factors, ECPF-1.
Extracellular Matrix Protection Factor 1 (ECPF-1), a novel inhibitor of Matrix Metalloprotease 13 (MMP-13) is chondroprotective in a serum-free culture model of primary human articular chondrocytes
Philadelphia
The pathogenic process that defines osteoarthritis (OA) is the imbalance between excess degradation of the extracellular matrix in articular cartilage and a decreased ability of chondrocytes to remodel the matrix. There are many factors that contribute to this disease including unchecked actions of matrix metalloproteinase 13 (MMP-13), an enzyme specific for the breakdown of collagen type II which is the main component of cartilage extracellular matrix. We have developed a three-dimensional, serum-free culture system to rear primary, human articular chondrocytes. In this study, we tested the effects of a member of the novel class of MMP inhibitors, Extracellular Matrix Protection Factors, ECPF-1.